Daniel Donen Davis Sells 30,000 Shares of Penumbra Inc (PEN) Stock
Penumbra Inc (NYSE:PEN) insider Daniel Donen Davis sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $88.80, for a total value of $2,664,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Penumbra Inc (NYSE PEN) traded up $0.65 during mid-day trading on Thursday, hitting $90.10. The company’s stock had a trading volume of 298,902 shares, compared to its average volume of 403,355. Penumbra Inc has a 1 year low of $67.95 and a 1 year high of $116.35. The stock has a market cap of $2,959.45, a P/E ratio of -409.55, a price-to-earnings-growth ratio of 93.43 and a beta of 0.16.
Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $79.17 million. During the same quarter in the prior year, the business earned ($0.04) EPS. The business’s revenue for the quarter was up 24.9% on a year-over-year basis. research analysts predict that Penumbra Inc will post -0.15 earnings per share for the current year.
A number of research analysts recently issued reports on the company. Canaccord Genuity boosted their price target on Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets upped their target price on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. JPMorgan Chase & Co. downgraded Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $111.50.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.